Search PubMed⌕ Search

Biomedical subjects

K W Brunner

Publications and source records attributed to K W Brunner.

At least 109 records · Page 6Linked to original sources
PubMed1980

[Phase-II-study with vindesine (desacetyl-vinblastine-amide-sulfate) in advanced malignant diseases].

53 patients with advanced and measurable cancerr were treated with vindesine in doses of 3 mg/m2 (pretreated) and 4 mg/m2 (non pretreated) i.v. once weekly. 48 patients are evaluable for response: of 14 patients with squamous cell carcinoma of the lung, 1 partial remission (PR), 1 minor response (MR) and 1 no change (NC) were observed. In 5 patients with large cell carcinoma of the lung: 1 NC. In 3 with adenocarcinoma of the lung: 1 MR. One patient with nasopharyngeal carcinoma had progressive disease. Stable disease was observed in a patient with carcinoma of the tongue and in a patient with adenocarcinoma of the esophagus. Four patients with colorectal carcinoma had progressive disease. One MR was observed in a patient with breast cancer, while all of the other 3 patients had progressive disease. One carcinoma of the penis was stable. One MR was observed in a patient with Hodgkin's disease. One PR was observed in a case with no-Hodgkin's lymphoma. A patient with acute leukemia had progressive disease. Among 9 patients with malignant melanoma, 3 had an MR and 1 patient had stable disease. A patient with fibrosarcoma had progressive disease. Observed toxicity included leukopenia, thrombocytopenia, anemia, paresthesias, constipation, jaw pain, nausea, stomatitis, alopecia, loss of taste, pruritus and skin rash, weakness and fatigue.

Adenocarcinoma↗
PubMed1980

[Adjuvant chemotherapy in soft tissue sarcomas].

21 patients with soft tissue sarcomas were treated after surgery with adriamycin alone or in combination with other drugs. 13 patients had additional local radiotherapy. 12 of thde 21 patients received chemotherapy as an adjuvant to surgery. 19 patients concurrently receiving palliative treatment for advanced soft tissue sarcoma in the form of adriamycin and adriamycin combinations served as controls. Results collected to date point to an improvement in the prognosis of soft tissue sarcomas, when radical surgery is followed by intensive subsequent cytostatic treatment. However, the present results await confirmation from prospective randomized studies now taking place. Some of the side effects of this treatment were very pronounced and led to the premature interruption of the trial in 24% of cases.

Adolescent↗
PubMed1980

Simultaneous hormone- and chemotherapy, compared with hormone therapy followed by chemotherapy in the treatment of metastasising mammary carcinoma--preliminary results of a current study.

The preliminary results of an on-going SAKK study on metastasising mammary cancinoma are reported. At the time of writing 210 cases are already evaluable. This study seeks to investigate the question of the necessary intensity of polychemotherapy and also the problem of whether cytostatic therapy should be begun at the same time as hormonal therapy or just after failure of this measure. At present no definite answer is available. The results point to a new, possibly important aspect of the treatment of metastasising mammary carcinoma.

Antineoplastic Agents↗
PubMed1979

A comparative trial of daunorubicin, cytosine arabinoside, and thioguanine, and a combination of the three agents for the treatment of acute myelocytic leukemia.

In this study 523 previously untreated patients with acute myelocytic leukemia were randomly allocated to induction therapy with daunorubicin 60 mg/M2 daily X 3, cytosine arabinoside and thioguanine 100 mg/M2 each every 12 hours until marrow hypoplasia was achieved, or a 5-day course of the three drugs with daunorubicin 100 mg/M2 given on dav 1 and cytosine arabinoside plus thioguanine each given at a dose of 100 mg/M2 every 12 hours for five days. All patients received cyclophosphamide 600 mg/M2 followed in 24 hours by hydroxyurea 500 mg/M2 every six hours for four doses monthly for maintenance therapy. Patients were randomized to receive one of three antimetabolite treatments beginning 24 hours after the last dose of hydroxyurea each month for seven days. One such treatment consisted of 6-mercaptopurine 100 mg/M2 daily, another group received 6-thioguanine at the same dose daily, and the third group received 50 mg/M2 of both antimetabolites daily. There were no significant differences in complete response rate, remission duration, or survival among the various treatment groups.

Adult↗
PubMed1978

[Interdisciplinary therapeutic planning in the treatment in malignant lymphoma and its results].

The development of curative treatment for malignant lymphoma over the last few years is described. Hodgkin's disease and non-Hodgkin lymphomas are discussed separately. The current improved cure rates for Hodgkin's disease have become possible only with more exact determination of disease stage and a clinically relevant histological classification and definition of other risk factors. These prognostic criteria provide the basis for determining whether radiotherapy alone, chemotherapy alone, or a combination of radiotherapy and chemotherapy offers the best chance for cure. --For the much more heterogenous disease group of non-Hodgkin lymphomas, a similar line of development is in progress. Here better forms of chemotherapy have been of primary importance and have significantly improved the prospects of cure, especially for cases in stage III and IV with unfavorable histologies. Combination treatment with radio- and chemotherapy is still in the developmental stage for non-Hodgkin lymphomas. The place of large volume radiotherapy such as total body or total abdominal irradiation has still to be determined.

Hodgkin Disease↗
PubMed1978

[Simultaneous hormonal and drug therapy, compared to hormonal therapy, followed by chemotherapy, in the treatment of metastasizing breast neoplasms. Preliminary results of an ongoing study].

The preliminary results of a still ongoing phase III study in patients with previously untreated metastatic breast cancer are reported. 210 cases are already evaluable. In this study patients are randomized to hormonotherapy either concurrently with combination chemotherapy or alone, chemotherapy being delayed until the occurrence of tumor progression. In both groups patients are further randomly allocated to 3 chemotherapy programs. So far there appear to be differences between remission rates, but not with regard to survival course.

Antineoplastic Agents↗
PubMed1978

[The state of hormone and chemotherapy in breast neoplasms].

Several decisive developments have emerged during the past few years in the hormonal treatment and chemotherapy receptors should make for a more selective and successful application of hormone therapy. In the field of chemotherapy, highly active substances have been developed. Two groups of routine treatment may be defined: the first employs combinations of cytoxan, methotrexate, 5-fluorouracil and prednisone, and the other, combinations of these agents with the highly active adriamycin. With these combinations, remissions lasting an average of over one year, with significantly prolonged survival, can be achieved in about two thirds of patients. It remains uncertain whether initial addition of hormone treatment to the chemotherapy is of definite advantage. Modern chemotherapy appears to have been especially beneficial in altering the course in patients with poor prognosis. The newest development is the use of chemotherapy postoperatively, i.e. so-called adjuvant chemotherapy. For the present this should only be done within controlled studies and in patients with histologically proven axillary lymph node metastases.

Androgens↗
PubMed1978

[Antiestrogens: a new endocrine treatment possibility in metastasizing breast neoplasms. Experiences of the Swiss Cooperative Cancer Study Group with tamoxifen].

The detection of specific hormone receptors in normal and tumor tissue has brought new insight into the mechanisms of action of hormones and anti-hormones. The Swiss Cooperative Cancer Study Group (SAKK) has evaluated the antitumor effect of the new antiestrogenic substance tamoxifen in metastatic breast cancer. 158 postmenopausal patients treated with 20 mg/d tamoxifen by mouth are evaluable at present time. Complete and good partial remissions were achieved in 39 patients (25%) largely with soft tissue but also lung and bone metastases. Tamoxifen was well tolerated and caused few serious complications such as thrombosis/pulmonary embolism and hypercalcemia. These results confirm already published experience with tamoxifen, which may replace the estrogens as the primary endocrine treatment in postmenopausal mammary carcinoma metastasizing to soft tissues, lung and bone.

Bone Neoplasms↗
PubMed1978

[Combination of adriamycin and cis-diammine-dichloro-platinum (II) in the treatment of advanced, therapy-resistant, ovarian carcinoma (author's transl)].

Adriamycin (doxorubicin, Adriblastin) and cis-diammine-dichloro-platinum (II) (DDP, NSC 119 875) were used in the treatment of 18 patients with ovarian carcinoma, usually after intensive pre-treatment, both in a dosage of 50 mg/m2 once every 4 weeks. Forced diuresis was initiated at the same time. On average three such treatments were given. Six patients showed partial remission defined as decrease of tumour mass by more than 50% or as almost complete disappearance of ascites during more than two months without concomitant diuretic treatment. The remission time was 2+, 3, 3+, 3.5, 7+, and 9+ months. In all patients severe gastrointestinal toxicity occurred, however the myelosuppressive action was only moderate. Nephrotoxicity was negligible. Combined chemotherapy with Adriblastin and DDP thus seems effective even in intensively pretreated patients with ovarian carcinoma.

Adult↗